Prevalence and dynamics of Lactobacillus sp. in the lower respiratory tract of patients with cystic fibrosis

Fangous, Marie-Sarah; Lazzouni, Ismaïl; Alexandre, Youenn; Gouriou, S.; Boisramé, Sylvie; Vallet, Sophie; Bihan, Jean Le; Ramel, Sophie; Héry-Arnaud, Geneviève; Berre, Rozenn Le

doi:10.1016/j.resmic.2018.03.005

Cited by 9 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we screened for new lung-adapted probiotic strains with anti- P. aeruginosa abilities. This screening was based on a previous work, which studied the prevalence of lactobacilli in the lung of CF patients in regard to their P. aeruginosa colonisation status [ 17 ]. As no difference in species diversity or frequency was observed, we secondly screened a representative sample of 50 strains for their in vitro ability to inhibit two virulence factors produced by P. aeruginosa, the elastase and pyocyanine.…”

Section: Discussionmentioning

confidence: 99%

“…As lactobacilli produce acids that directly inhibit P. aeruginosa, bactericidal assays cannot be used for screening [ 7 ]. Fifty Lactobacillus strains previously isolated from respiratory samples from patients with CF [ 17 ] were thus screened in vitro for their ability to decrease the synthesis of 2 P. aeruginosa QS-dependent virulence factors, pyocyanin and elastase. P. aeruginosa PAO1 was chosen as the reference strain for all experiments [ 50 ].…”

Section: Methodsmentioning

confidence: 99%

“…In this study, in the light of our previous results, we’d like first to screen for new lung-adapted probiotic strains to consider for in vivo studies, and second to confirm the use of the respiratory route for their administration against P. aeruginosa lung infection . The screening involved Lactobacillus isolates that we previously obtained from CF expectorations [ 17 ]. It was based on their capacity to inhibit two P. aeruginosa QS-dependent virulence factors (elastase and pyocyanin).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Priming with intranasal lactobacilli prevents Pseudomonas aeruginosa acute pneumonia in mice

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Increasing resistance to antibiotics of Pseudomonas aeruginosa leads to therapeutic deadlock and alternative therapies are needed. We aimed to evaluate the effects of Lactobacillus clinical isolates in vivo, through intranasal administration on a murine model of Pseudomonas aeruginosa pneumonia. Results We screened in vitro 50 pulmonary clinical isolates of Lactobacillus for their ability to decrease the synthesis of two QS dependent-virulence factors (elastase and pyocyanin) produced by Pseudomonas aeruginosa strain PAO1. Two blends of three Lactobacillus isolates were then tested in vivo: one with highly effective anti-PAO1 virulence factors properties (blend named L.rff for L. rhamnosus, two L. fermentum strains), and the second with no properties (blend named L.psb, for L. paracasei, L. salivarius and L. brevis). Each blend was administered intranasally to mice 18 h prior to PAO1 pulmonary infection. Animal survival, bacterial loads, cytological analysis, and cytokines secretion in the lungs were evaluated at 6 or 24 h post infection with PAO1. Intranasal priming with both lactobacilli blends significantly improved 7-day mice survival from 12% for the control PAO1 group to 71 and 100% for the two groups receiving L.rff and L.psb respectively. No mortality was observed for both control groups receiving either L.rff or L.psb. Additionally, the PAO1 lung clearance was significantly enhanced at 24 h. A 2-log and 4-log reduction was observed in the L.rff + PAO1 and L.psb + PAO1 groups respectively, compared to the control PAO1 group. Significant reductions in neutrophil recruitment and proinflammatory cytokine and chemokine secretion were observed after lactobacilli administration compared to saline solution, whereas IL-10 production was increased. Conclusions These results demonstrate that intranasal priming with lactobacilli acts as a prophylaxis, and avoids fatal complications caused by Pseudomonas aeruginosa pneumonia in mice. These results were independent of in vitro anti-Pseudomonas aeruginosa activity on QS-dependent virulence factors. Further experiments are required to identify the immune mechanism before initiating clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Priming with intranasal lactobacilli prevents Pseudomonas aeruginosa acute pneumonia in mice

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our study, we screened for new lung-adapted probiotic strains with anti-P. aeruginosa abilities. This screening was based on a previous work, which studied the prevalence of lactobacilli in the lung of CF patients in regard to their P. aeruginosa colonisation status (38). As no difference in species diversity or frequency was observed, we secondly screened a representative sample of 50 strains for their in vitro ability to inhibit two virulence factors produced by P. aeruginosa, the elastase and pyocyanine.…”

Section: Discussionmentioning

confidence: 99%

Priming with intranasal lactobacilli prevents Pseudomonas aeruginosa acute pneumonia in mice.

Fangous

Gosset

Galakhoff

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background : Increasing resistance to antibiotics of Pseudomonas aeruginosa leads to therapeutic deadlock and alternative therapies are needed. We aimed to evaluate the effects of Lactobacillus clinical isolates in vivo, through intranasal administration on a murine model of Pseudomonas aeruginosa pneumonia.Results : We screened in vitro 50 pulmonary clinical isolates of Lactobacillus for their ability to decrease the synthesis of two QS dependent-virulence factors (elastase and pyocyanin) produced by Pseudomonas aeruginosa strain PAO1.Two blends of three Lactobacillus isolates were then tested in vivo: one with highly effective anti-PAO1 virulence factors properties (blend named L.rff for L. rhamnosus, two L. fermentum strains), and the second with no properties (blend named L.psb, for L. paracasei, L. salivarius and L. brevis). Each blend was administered intranasally to mice 18h prior to PAO1 pulmonary infection. Animal survival, bacterial loads, cytological analysis, and cytokines secretion in the lungs were evaluated at 6 or 24h post infection with PAO1. Intranasal priming with both lactobacilli blends significantly improved 7-day mice survival from 12% for the control PAO1 group to 71% and 100% for the two groups receiving L.rff and L.psb respectively. No mortality was observed for both control groups receiving either L.rff or L.psb. Additionally, the PAO1 lung clearance was significantly enhanced at 24h. A 2-log and 4-log reduction was observed in the L.rff+PAO1 and L.psb+PAO1 groups respectively, compared to the control PAO1 group. Significant reductions in neutrophil recruitment and proinflammatory cytokine and chemokine secretion were observed after lactobacilli administration compared to saline solution, whereas IL-10 production was increased. Conclusions : These results demonstrate that intranasal priming with lactobacilli acts as a prophylaxis, and avoids fatal complications caused by Pseudomonas aeruginosa pneumonia in mice. These results were independent of in vitro anti-Pseudomonas aeruginosa activity on QS-dependent virulence factors. Further experiments are required to identify the immune mechanism before initiating clinical trials.

show abstract

“…In this regard, it might be argued that strains isolated from CF lung, presumably already adapted to such a harsh environment and able to compete with the indigenous microflora, can provide a valuable source of lactobacilli. Indeed, the high prevalence of lactobacilli carriage has been found in CF patients with 61% of them harboring at least one strain of Lactobacillus in their sputum, with L. rhamnosus, L. fermentum, L. paracasei and L. gasseri being the four most common species [80]. An eight-month follow-up of 26 patients revealed that in the majority of them (20/26), the colonization was transient, while 23% of them (6/26) were chronically colonized [80], suggesting a high degree of adaptation to the local conditions of the respective strains.…”

Section: Lung Colonization Capabilitymentioning

confidence: 99%

Lung-Directed Bacteriotherapy in Cystic Fibrosis: Could It Be an Option?

et al. 2022

View full text Add to dashboard Cite

Due to the alarming spread of bacterial resistance to conventional drugs, the sole use of antibiotics to fight lung infections in cystic fibrosis (CF) is not resolutive, and novel strategies to replace or complement the use of antibiotics are highly desirable. Among these strategies, the use of probiotics is emerging as a particularly attractive approach. Probiotic administration via the oral route has demonstrated an ability to improve lung function and to reduce infection and exacerbation rates in CF patients through mechanisms mainly attributable to the gut–lung axis. Nevertheless, some studies reported no beneficial effect of probiotic intake suggesting that there is margin for improvement of such innovative intervention in CF. The present review aims to address the rationale behind probiotic use in CF and discuss the hypothesis that nasal/aerosol administration of appropriate probiotic strains may help to exert a direct beneficial effect on the respiratory tract, increasing the effectiveness of probiotic interventions in CF patients.

show abstract

Prevalence and dynamics of Lactobacillus sp. in the lower respiratory tract of patients with cystic fibrosis

Cited by 9 publications

References 19 publications

Priming with intranasal lactobacilli prevents Pseudomonas aeruginosa acute pneumonia in mice

Priming with intranasal lactobacilli prevents Pseudomonas aeruginosa acute pneumonia in mice

Priming with intranasal lactobacilli prevents Pseudomonas aeruginosa acute pneumonia in mice.

Lung-Directed Bacteriotherapy in Cystic Fibrosis: Could It Be an Option?

Contact Info

Product

Resources

About